Deal Details

Sale to GI Partners

---

Summary

About

Clinical Ink, Inc. (“Clinical Ink” or the “Company”) was recently acquired by GI Partners. Existing investor NovaQuest Capital Management, L.L.C. (“NovaQuest”) will continue as a minority investor in the Company and the senior management team also invested significantly in the transaction. Terms of the transaction were not disclosed.

Clinical Ink offers data certainty from source to submission during clinical trials. The Company’s Lumenis eSource clinical technology is a suite of solutions for capturing and integrating clinical trial electronic study data from sites, clinicians, and patients in real time. Through configurable direct data capture (DDC), electronic clinical outcome assessment (eCOA), electronic patient reported outcomes (ePRO), and eConsent modules, the Company’s eSource Ecosystem has been deployed across 300 studies, in all Phases (I–IV). Clinical Ink is headquartered in Horsham, Pennsylvania.

GI Partners is a private investment firm that has raised over $21 billion in capital from leading institutional investors around the world to invest in private equity, real estate, and data infrastructure strategies. The private equity team invests primarily in companies in the Healthcare, IT Infrastructure, Services, and Software sectors. GI Partners is based in San Francisco, California.

NovaQuest Capital Management is a leading investor in life sciences and healthcare. NovaQuest was formed in 2000 and manages over $2.5 billion through its Product Finance and Private Equity strategies. The investment team consists of highly seasoned professionals with significant operating and investment experience and deep life science and healthcare expertise. NovaQuest is headquartered in Raleigh, North Carolina.

---

CONTACT US TO LEARN MORE